BioFactura is committed to identifying and fulfilling unmet global biomedical and national biodefense needs. BioFactura is applying its StableFast^TM Biomanufacturing Platform to develop a portfolio of high-value biosimilars (generic biological drugs). The Company is also focused on bringing to market a drug for the treatment of smallpox and is conducting research and development of a Marburg therapeutic. BioFactura is evaluating other opportunities in both commercial and biodefense markets.